Beyond Sleep: Why Alkermes' Orexin ADHD Data Could Signal the Next Neuroscience Revolution

For decades, the treatment of attention-deficit hyperactivity disorder has operated within a narrow pharmacological corridor. Stimulants that amplify dopamine and norepinephrine signaling have dominated the landscape since the 1950s. Non-stimulant alternatives like atomoxetine and viloxazine arrived later, offering a different mechanism but still working within the same broad framework of monoamine modulation. The field has been, in a word, static. On September 21, 2026, Alkermes announced Phase 1b data for ALKS 7290, an oral orexin 2 receptor agonist, that suggests the corridor may be about to widen considerably.

The results are early, and the company is careful to say so. The Phase 1b study enrolled 50 adults with ADHD in a double-blind, placebo-controlled trial and was not designed or powered to detect statistically significant differences between groups. What it was designed to do was establish proof of concept, and on that measure, the data are striking. At day 14, patients receiving the 50 mg dose showed a median 19-point reduction from baseline on the Adult ADHD Investigator Symptom Rating Scale, a 54-point clinician-administered measure of symptom severity. The 20 mg group showed a 14-point reduction. Baseline scores averaged approximately 39, placing participants in the range of substantial symptom burden. Improvements appeared as early as day 6 and were observed across both the inattentive and hyperactivity subscales. On the Clinical Global Impression-Severity scale, patients shifted from markedly or moderately ill to mildly ill. No serious adverse events were reported, and no participants in the active treatment groups discontinued the study.

What Orexin Actually Does in the Brain

To understand why these results matter, it helps to understand what orexin is and what it does beyond regulating sleep. Orexin is a neuropeptide produced in the lateral hypothalamus that plays a central role in wakefulness, but its downstream effects extend well beyond keeping people awake. The orexin system engages neural circuits involved in attention, cognition, working memory, and mood regulation. These are precisely the domains that ADHD disrupts. The hypothesis that orexin receptor agonism could address ADHD symptoms is not a stretch of the imagination. It is a logical extension of what the neuroscience has been suggesting for years.

What has been missing is clinical evidence. ALKS 7290 is the first orexin receptor agonist to generate data in ADHD patients, and the Phase 1b results provide that evidence for the first time. The EEG-based biomarkers and objective cognitive performance tests included in the study showed treatment effects across processing speed, information processing, working memory, and attention, supporting the mechanistic story and informing the dose selection for the Phase 2 program. A well-powered Phase 2 study enrolling approximately 312 adults is already underway, with data expected in 2027.

The GLP-1 Comparison and What It Gets Right

The orexin agonist class has been described by some observers as the GLP-1s of neuroscience, a framing that is both useful and worth interrogating carefully. The comparison is useful because it captures something real: a mechanism that was understood primarily in the context of one condition, narcolepsy in the case of orexin, is now being explored across a much broader range of disorders where the underlying biology turns out to be relevant. Takeda's Orzeyful, approved by the FDA in August 2026 as the first orexin agonist for narcolepsy type 1, established the class as clinically viable. Alkermes is now attempting to do what Lilly and others did with GLP-1 receptor agonists: take a validated mechanism and ask what else it can do.

The comparison is worth interrogating because the GLP-1 story involved a mechanism with effects on peripheral metabolism that turned out to have broad systemic implications. The orexin story is more centrally focused, operating within the brain's arousal and attention networks. That focus may actually be an advantage in ADHD, where the target is specific and the mechanism is directly relevant. But it also means the expansion thesis depends on demonstrating that orexin agonism can produce clinically meaningful effects in conditions beyond sleep disorders, which is exactly what the ALKS 7290 Phase 1b data begin to show.

The ADHD Market and Why This Mechanism Is Different

ADHD affects an estimated 366 million adults worldwide, and diagnosis rates have been rising steadily. The current treatment landscape is dominated by stimulants, which carry scheduling restrictions, abuse potential concerns, and cardiovascular considerations that limit their use in certain patient populations. Non-stimulant options exist but have generally shown more modest efficacy. A non-stimulant mechanism that produces clinically meaningful symptom reduction without serious adverse events would address a genuine gap in the treatment toolkit, particularly for adults who cannot tolerate stimulants or for whom stimulants are contraindicated.

The tolerability profile of ALKS 7290 in the Phase 1b study is notable in this context. The most common adverse events were mild and included insomnia, urinary frequency, dizziness, and constipation. Urinary frequency is a known class effect of orexin agonists, observed with Orzeyful as well. No clinically significant findings were observed in hepatic or renal parameters, vital signs, or ECGs. The maximum tolerated dose was not reached in the healthy volunteer portion of the study. For a drug class entering a new indication, that safety profile is an encouraging starting point.

Alkermes and the Orexin Portfolio Strategy

The ALKS 7290 data arrive in the context of a broader orexin strategy at Alkermes that is worth understanding. The company's lead orexin asset, alixorexton, is in late-stage development for narcolepsy type 2 and idiopathic hypersomnia, conditions where no orexin agonist is currently approved. A third asset, ALKS 4510, is in Phase 1 development for fatigue associated with multiple sclerosis and Parkinson's disease. The company's CEO Blair Jackson has described ALKS 7290 as a potential company changer, a characterization that reflects the scale of the ADHD market relative to Alkermes' current commercial footprint.

That framing is commercially understandable, but the more interesting implication is scientific. If orexin agonism can produce meaningful effects in ADHD, narcolepsy, idiopathic hypersomnia, and MS-related fatigue, the orexin system begins to look less like a sleep regulator with some peripheral effects and more like a central node in the brain's arousal and attention architecture, one that is relevant across a range of conditions that share impairments in wakefulness, focus, and cognitive performance. That is a different and more expansive thesis than the one the field started with.

What the Phase 2 Data Will Need to Show

The Phase 1b results are a proof of concept, not a proof of efficacy. The Phase 2 study, with its 312 participants and four-week treatment duration, will need to demonstrate statistically significant improvement on the primary endpoint of AISRS total score change from baseline compared to placebo. It will also need to show that the tolerability profile observed in the smaller study holds at scale, and that the dose-dependent effects seen at two weeks are maintained or enhanced over a longer treatment period.

ADHD trials have a history of generating early signals that do not survive larger, longer studies. The field is appropriately cautious about Phase 1b data in a condition where placebo response rates can be substantial and where the patient population is heterogeneous. The 2027 Phase 2 readout will be the moment that determines whether ALKS 7290 is a genuine addition to the ADHD treatment landscape or an interesting mechanism that did not translate at scale.

What the Phase 1b data establish, with reasonable confidence, is that the orexin system is biologically active in ADHD and that pharmacological engagement of the OX2 receptor produces measurable effects on the neural circuits that underlie the condition. That is not a small finding. It is the first clinical evidence that a new mechanism of action is worth pursuing seriously in a therapeutic area that has been waiting for one for a long time.